Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis knee pain. | Novartis has terminated a phase 2 trial evaluating an ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline. CEO Vas Narasimhan said ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, Texas, Indiana, and New Jersey.

The deal with Novartis includes the potential for further out-licensing from GSK's oncology pipeline, and the UK-based firm is likely only go it alone if a potential market leader in the area ...

Steffen Lang, president, operations, executive committee member, Novartis, discusses what to expect from Novartis over the next decade in terms of technological innovations.

While organic growth continues to drive business, NVS is focused on strategic bolt-in acquisitions to strengthen its pipeline ...

Novartis' drug segment is poised for steady cash flows driven by new pipeline products and existing drugs. Novartis' strategy to focus largely in areas of unmet medical need should strengthen the ...

Steffen Lang, president, operations, executive committee member, Novartis, shares strategic insights on how pharma supply ...

Novartis also says it has “multiple significant in-market and pipeline assets in each of these areas” that “address high disease burden and have substantial growth potential.” Commenting ...